Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive condition that can be caused by genetic mutations or aging, and is characterized by accumulating heart damage that ultimately leads to symptoms of heart failure. In ATTR-CM,…
The most common signs of transthyretin amyloid cardiomyopathy (ATTR-CM) are those typically associated with heart failure, although problems in the nervous system or other tissues can also occur. ATTR-CM is a type of cardiac amyloidosis,…
A diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM) is typically reached through a series of tests to identify signs of the disease and rule out related disorders. ATTR-CM is a type of heart amyloidosis, a group…
The treatment of transthyretin amyloid cardiomyopathy (ATTR-CM) is a multidisciplinary effort involving interventions to slow disease progression and manage symptoms. ATTR-CM is a form of amyloidosis, where protein clumps, called amyloid deposits, accumulate in tissues.
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a form of heart disease that’s typically caused by genetic mutations or aging. Determining the root cause of ATTR-CM can help guide treatment decisions, understand prognosis, and determine if family…
Latest News & Community Perspectives
Women with transthyretin amyloid cardiomyopathy (ATTR-CM) show differences in disease features and greater physical limitations than men, but are less likely to be given certain treatments, according to a study in Spain. In addition,…
Blood levels of the transthyretin (TTR) protein at the start of Vyndaqel (tafamidis) treatment and after one month may help identify which patients with wild-type transthyretin amyloidosis with cardiomyopathy (ATTR-CM) are responding well and…
The U.S. Food and Drug Administration (FDA) has lifted its hold on a large-scale clinical trial evaluating nexiguran ziclumeran, Intellia Therapeutics’ gene-editing therapy candidate, known as nex-z for short, in adults with transthyretin…
Homes and landmarks across the U.S. and other countries will once again light up in red throughout March for Amyloidosis Awareness Month as the Amyloidosis Foundation reprises its annual “Light the Night for Amyloidosis”…
Attruby (acoramidis) slows disease progression and significantly reduces death and cardiovascular-related hospitalizations in adults with hereditary or wild-type transthyretin amyloid cardiomyopathy (ATTR-CM) across several subgroups, according to new analyses of data from a…
Blood levels of signaling molecules that promote tissue scarring, or fibrosis, are elevated in people with transthyretin amyloid cardiomyopathy (ATTR-CM), and higher levels of these molecules are associated with worse clinical outcomes for ATTR-CM…
The U.S. Food and Drug Administration (FDA) has lifted a clinical hold on a Phase 3 clinical trial testing the investigational gene-editing therapy, nexiguran ziclumeran (nex-z), in adults with hereditary transthyretin amyloidosis with polyneuropathy…
More than half of adults with hereditary ATTR amyloidosis with cardiomyopathy (hATTR-CM), a condition marked by heart damage, also have multi-nerve damage, according to a new study from the University of Toronto. The findings…
Treatments that target the transthyretin (TTR) protein, either by stabilizing it or reducing its production, were associated with about a one-third lower risk of death and cardiovascular hospitalizations in people with transthyretin amyloid cardiomyopathy…
The European Commission has expanded the indication of Amvuttra (vutrisiran) to include adults with ATTR amyloidosis with cardiomyopathy, or heart damage (ATTR-CM), regardless of whether they carry disease-causing mutations. “Estimates show approximately 100,000 people…